跳至主要内容
临床试验/NCT03333239
NCT03333239Unknown不适用

Short-term, Long-term and Cost-effectiveness of Treating Depression and Anxiety Disorders in Children and Adolescents - a Randomized Controlled Trial

Universitätsklinikum Hamburg-Eppendorf0 个研究点目标入组 420 人开始时间: 2017年12月22日最近更新:
适应症

试验速览

阶段
不适用
入组人数
420
主要终点
Change from baseline children´s psychiatric symptomatology at 24 months

研究概览

简要总结

The current study will evaluate and compare the effectiveness of cognitive-behavioral and psychodynamic therapy. Therefore 420 children and adolescents (ages 8-16 years) with depression and/or anxiety disorder will be randomly assigned to a treatment or a control condition. The intervention´s short-term effectiveness and sustainability as well as cost-effectiveness will be examined over a 5 year period for each participant.

详细描述

This study aims to optimize patient-centered care and to ensure scientific and legal approval of cognitive-behavioral and psychodynamic therapy for children and adolescents in the German health-care system. This prospective, randomized and controlled trial will therefore compare psychodynamic and cognitive behavioral therapy with a low-frequency family intervention (control intervention) for children and adolescents with depression and anxiety disorder. Number of diagnoses or fulfilled diagnostic criteria - diagnosed by a trained psychologist who is blind for treatment condition - will be the primary outcome. Secondary outcomes are patients´ and parents´ strain caused by symptoms, patients´ quality of life, global and family functioning and treatments´ cost effectiveness are secondary outcomes.

Patients will be recruited at the end of an inpatient hospital stay in northern Germany (Hamburg and Bremen) in two clinics for child and adolescent psychiatry and in surgery. After gathering informed consent from parents and patients, the latter will be randomly assigned to one type of outpatient treatment (psychodynamic, cognitive behavioral therapy or family intervention). Psychodynamic and cognitive-behavioral therapy as well as the control intervention will be provided manual-based. Treatment sessions will be audio recorded to control adherence.

Data will be collected annually over a period of five years starting at the beginning of treatment. This allows examination of varying treatment intervals as well as the sustainability and health economics of therapy effects.

To analyze data, comparisons of means will be performed. Groupwise analyses of interaction will be performed for inferential testing of differences in subgroups. Differences in therapy effects will be inferentially analyzed by multifactor analysis of covariance, analysis of variance or logistic regression. Interaction effects and predicting variables are of special interest.

In a Subsample of 32 depressive adolescents (ages 13-16) patients expectations before and experiences whilst therapy will be analyzed by a mixed-methods-approach.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
8 Years 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • diagnosis of a depressive disorder (ICD-10; F30-F39) or an anxiety disorder (ICD-10; F40-F42)
  • informed consent
  • ages 8 to 16 years

排除标准

  • psychotic disorders, eating disorders, substance use related disorders (except caffeine and nicotine), autism spectrum disorders, mutism, personality disorders
  • neurologic disorders
  • severe mental retardation (filling out questionnaires and interview are not feasible)
  • low command of the german language

结局指标

主要结局

Change from baseline children´s psychiatric symptomatology at 24 months

时间窗: baseline and 24 months

Children´s psychiatric symptomatology will be assessed in all groups (intervention groups and control group) by an external independent interview (Kiddie-SADS; Kaufman et al., 1996). The Kiddie-SADS interview will be conducted by a trained rater external to the project.

Change from baseline children´s psychiatric symptomatology at 60 months

时间窗: baseline and 60 months

Children´s psychiatric symptomatology will be assessed in all groups (intervention groups and control group) by an external independent interview (Kiddie-SADS; Kaufman et al., 1996). The Kiddie-SADS interview will be conducted by a trained rater external to the project.

Change from baseline children´s psychiatric symptomatology at 12 months

时间窗: baseline and 12 months

Children´s psychiatric symptomatology will be assessed in all groups (intervention groups and control group) by an external independent interview (Kiddie-SADS; Kaufman et al., 1996). The Kiddie-SADS interview will be conducted by a trained rater external to the project.

Change from baseline children´s psychiatric symptomatology at 48 months

时间窗: baseline and 48 months

Children´s psychiatric symptomatology will be assessed in all groups (intervention groups and control group) by an external independent interview (Kiddie-SADS; Kaufman et al., 1996). The Kiddie-SADS interview will be conducted by a trained rater external to the project.

Change from baseline children´s psychiatric symptomatology at 36 months

时间窗: baseline and 36 months

Children´s psychiatric symptomatology will be assessed in all groups (intervention groups and control group) by an external independent interview (Kiddie-SADS; Kaufman et al., 1996). The Kiddie-SADS interview will be conducted by a trained rater external to the project.

次要结局

  • Change from baseline children´s anxiety at 36 months(baseline and 36 months)
  • Change from baseline children´s depressive symptomatology at 12 months(baseline and 12 months)
  • Change from baseline children´s depressive symptomatology at 60 months(baseline and 60 months)
  • Change from baseline children´s anxiety at 60 months(baseline and 60 months)
  • Change from baseline children´s depressive symptomatology at 36 months(baseline and 36 months)
  • Change from baseline children´s depressive symptomatology at 24 months(baseline and 24 months)
  • Change from baseline children´s depressive symptomatology at 48 months(baseline and 48 months)
  • Change from baseline parent reported children´s psychiatric symptoms at 36 months(baseline and 36 months)
  • Change from baseline children´s self reported psychiatric symptoms at 36 months(baseline and 36 months)
  • Change from baseline children´s self reported psychiatric symptoms at 48 months(baseline and 48 months)
  • Change from baseline children´s structural functioning at 36 months(baseline and 36 months)
  • Change from baseline children´s anxiety at 12 months(baseline and 12 months)
  • Change from baseline parent reported children´s psychiatric symptoms at 60 months(baseline and 60 months)
  • Change from baseline children´s self reported psychiatric symptoms at 24 months(baseline and 24 months)
  • Change from baseline children´s structural functioning at 60 months(baseline and 60 months)
  • Change from baseline children´s global impairment at 36 months(baseline and 36 months)
  • Change from baseline children´s anxiety at 24 months(baseline and 24 months)
  • Change from baseline children´s anxiety at 48 months(baseline and 48 months)
  • Change from baseline parent reported children´s psychiatric symptoms at 24 months(baseline and 24 months)
  • Change from baseline children´s health related quality of life at 36 months(baseline and 36 months)
  • Change from baseline parent reported children´s psychiatric symptoms at 12 months(baseline and 12 months)
  • Change from baseline parent reported children´s psychiatric symptoms at 48 months(baseline and 48 months)
  • Change from baseline children´s self reported psychiatric symptoms at 12 months(baseline and 12 months)
  • Change from baseline children´s self reported psychiatric symptoms at 60 months(baseline and 60 months)
  • Change from baseline children´s structural functioning at 12 months(baseline and 12 months)
  • Change from baseline children´s health related quality of life at 12 months(baseline and 12 months)
  • Change from baseline relational functioning at 36 months(baseline and 36 months)
  • Change from baseline children´s structural functioning at 24 months(baseline and 24 months)
  • Change from baseline children´s structural functioning at 48 months(baseline and 48 months)
  • Change from baseline children´s global functioning at 48 months(baseline and 48 months)
  • Change from baseline children´s health related quality of life at 24 months(baseline and 24 months)
  • Change from baseline children´s health related quality of life at 48 months(baseline and 48 months)
  • Change from baseline relational functioning at 24 months(baseline and 24 months)
  • Change from baseline relational functioning at 48 months(baseline and 48 months)
  • Change from baseline relational functioning at 60 months(baseline and 60 months)
  • Change from baseline children´s global functioning at 12 months(baseline and 12 months)
  • Change from baseline children´s health related quality of life at 60 months(baseline and 60 months)
  • Change from baseline children´s global impairment at 12 months(baseline and 12 months)
  • Change from baseline children´s global impairment at 24 months(baseline and 24 months)
  • Change from baseline children´s global impairment at 48 months(baseline and 48 months)
  • Change from baseline children´s global impairment at 60 months(baseline and 60 months)
  • Change from baseline health economic data at 12 months(baseline and 12 months)
  • Change from baseline health economic data at 24 months(baseline and 24 months)
  • Change from baseline relational functioning at 12 months(baseline and 12 months)
  • Change from baseline children´s global functioning at 36 months(baseline and 36 months)
  • Change from baseline children´s global functioning at 24 months(baseline and 24 months)
  • Change from baseline children´s global functioning at 60 months(baseline and 60 months)
  • Change from baseline health economic data at 48 months(baseline and 48 months)
  • Change from baseline health economic data at 36 months(baseline and 36 months)
  • Change from baseline health economic data at 60 months(baseline and 60 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Silke Wiegand-Grefe, Prof. Dr.

Prof. Dr.

Universitätsklinikum Hamburg-Eppendorf

相似试验

Short-term, Long-term and Cost-effectiveness of... | 临床试验